Determinants of the duration of B-cell depletion after rituximab in a pediatric population

Rayan Affes; Anne-Laure Lapeyraque; Camille Laroche; Roxane Labrosse; Alexandra Cambier; Emile Demers; Adrien Flahault

doi:10.1093/ndt/gfad147

Determinants of the duration of B-cell depletion after rituximab in a pediatric population

Nephrol Dial Transplant. 2023 Dec 20;39(1):159-162. doi: 10.1093/ndt/gfad147.

Authors

Rayan Affes^{1

2}, Anne-Laure Lapeyraque^{1

2

3}, Camille Laroche^{1

2}, Roxane Labrosse⁴, Alexandra Cambier^{1

2

3}, Emile Demers^{1

5}, Adrien Flahault^{3

6

7}

Affiliations

¹ University of Montreal, Montreal, Quebec, Canada.
² Division of Nephrology, Department of Pediatrics, Sainte-Justine University Hospital, Montreal, Quebec, Canada.
³ CHU Sainte Justine Research Center, Montreal, Quebec, Canada.
⁴ Division of Allergy and Immunology, Department of Pediatrics, CHU Sainte-Justine, Montreal, Quebec, Canada.
⁵ Department of Pharmacy, Sainte-Justine University Hospital, Montreal, Quebec, Canada.
⁶ Service de Néphrologie, CHRU de Nancy, Vandoeuvre-lès-Nancy, France.
⁷ Université de Lorraine, Nancy, France.

PMID: 37433571
DOI: 10.1093/ndt/gfad147

No abstract available

MeSH terms

B-Lymphocytes*
Child
Humans
Immunologic Factors*
Lymphocyte Depletion
Rituximab / therapeutic use

Substances

Rituximab
Immunologic Factors

Grants and funding

FRQS